William Sutherland

Gene Mannheimer

Anthony Vendetti

Bradford Seagraves

Carl Byrnes

Joshua Cohen

Thomas McGovern

Tom McGovern

- Nutex Health reported strong preliminary Q2 2025 results, with **total revenue of $244 million**, a **220% increase** from Q2 2024, and **adjusted EBITDA of $73.3 million**, up from $6.8 million in the prior year period.  **[1479681_tx_346404_1]** **[1479681_tx_346404_6]** **[1479681_tx_346404_7]**  For the six months ended June 30, 2025, **net cash from operating activities was $78.2 million**.  **[1479681_tx_346404_1]** 
- The hospital division's revenue was **$236.3 million** in Q2 2025, with **$167.7 million (approximately 71%)** derived from independent dispute resolution (IDR) revenue.  **[1479681_tx_346404_6]**  The company has a **75%+ collection rate** on IDR legal determination wins and an **85%+ success rate** on claims submitted to arbitration.  **[1479681_tx_346404_6]** **[1479681_tx_346404_12]** 
- The Board of Directors authorized a **stock repurchase program of up to $25 million** of common stock over the next six months, effective July 30, 2025.  **[1479681_tx_346404_4]**  Nutex Health also has **over 15 hospital projects in development**, with two confirmed openings by the end of 2025.  **[1479681_tx_346404_3]** **[1479681_tx_346404_13]** 
- The company received a Nasdaq notice on August 20, 2025, for failing to timely file its Q2 2025 Form 10-Q and has until **October 20, 2025**, to complete the filing.  **[1479681_tx_346404_6]**  The accounting issue causing the delay does not impact previously reported key financial metrics.  **[1479681_tx_346404_6]**

Nutex Health (NUTX)